although
highli
pathogen
avian
influenza
virus
yet
acquir
abil
transmit
effici
among
human
increas
genet
divers
among
virus
continu
outbreak
avian
speci
underscor
need
effect
measur
control
prevent
human
viru
infect
addit
small
anim
model
therapeut
approach
virul
influenza
virus
evalu
need
studi
use
guinea
pig
model
evalu
rel
virul
select
avian
human
influenza
virus
demonstr
guinea
pig
infect
avian
human
influenza
virus
result
high
titer
viru
shed
nasal
wash
day
postinocul
p
propos
guinea
pig
may
serv
use
small
anim
model
test
efficaci
antivir
compound
treatment
may
use
antivir
strategi
highli
virul
strain
pandem
potenti
sinc
influenza
virus
subtyp
caus
devast
outbreak
poultri
asia
africa
europ
result
human
infect
overal
case
fatal
rate
increas
persist
genet
divers
virus
poultri
concomit
human
infect
indic
virus
remain
pandem
threat
despit
evid
limit
humantohuman
transmiss
virus
yet
exhibit
sustain
transmiss
among
human
virus
acquir
abil
result
pandem
could
unusu
sever
requir
multipl
control
measur
limit
morbid
mortal
associ
pandem
viru
vaccin
remain
primari
method
reduc
morbid
associ
season
influenza
viru
infect
due
divers
circul
virus
overal
timelin
manufactur
antigen
wellmatch
vaccin
may
avail
initi
stage
pandem
current
fdaapprov
influenza
viru
antivir
consist
adamantan
compound
amantidinerimantidin
neuraminidas
inhibitor
oseltamivir
zanamivir
howev
widespread
adamantin
resist
recent
document
among
season
strain
addit
major
clade
clade
isol
southeast
asia
oseltamivirresist
isol
also
report
given
potenti
resist
exist
antivir
identif
addit
therapeut
may
limit
replic
virus
therebi
reduc
morbid
transmiss
earli
stage
pandem
high
prioriti
interferon
ifn
respons
critic
compon
host
innat
antivir
respons
compound
trigger
enhanc
respons
alreadi
use
clinic
treat
number
viral
infect
accumul
research
suggest
engag
ifn
respons
prior
infect
may
viabl
therapeut
strategi
control
influenza
viru
infect
context
natur
infect
influenza
virus
induc
mice
human
level
induct
highli
variabl
strain
depend
furthermor
mice
render
ifn
defici
delet
receptor
show
increas
viral
titer
extrarespiratori
spread
follow
infect
virus
display
increas
morbid
mortal
follow
viru
infect
k
szretter
et
al
submit
public
studi
clearli
establish
ifn
pathway
critic
control
influenza
viru
infect
mice
mx
gtpase
one
mani
antivir
protein
induc
ifn
respons
mx
shown
significantli
contribut
control
respiratori
restrict
highli
pathogen
influenza
viru
strain
necessari
establish
influenzaresist
state
follow
prophylact
treatment
exogen
ifn
howev
standard
laboratori
mous
strain
includ
balbc
carri
delet
gene
comparison
guinea
pig
recent
found
effect
model
studi
influenza
viru
infect
transmiss
possess
function
mx
gene
highlight
model
ideal
studi
ifn
respons
influenza
viru
infect
variou
speci
use
anim
model
influenza
viru
infect
review
refer
howev
common
mammalian
model
use
influenza
viru
research
mous
suscept
infect
unadapt
human
influenza
virus
shed
viru
respiratori
tract
therefor
need
develop
addit
permiss
small
anim
model
influenza
viru
infect
exhibit
viru
shed
serial
sampl
collect
anim
model
allow
investig
determin
titer
durat
viru
shed
individu
anim
multipl
time
without
euthanasia
guinea
pig
model
shown
support
replic
contemporari
human
influenza
viru
strain
suscept
highli
pathogen
influenza
viru
strain
current
unknown
studi
assess
virul
highli
pathogen
pandem
virus
addit
lowpathogen
avian
human
virus
guinea
pig
model
demonstr
guinea
pig
natur
suscept
infect
avian
human
influenza
virus
highli
pathogen
virus
comparison
virus
low
pathogen
isol
upper
respiratori
tract
guinea
pig
later
time
postinfect
induc
sever
lung
lesion
abil
human
ifn
inhibit
viru
replic
limit
virusinduc
patholog
follow
infect
virus
examin
found
prophylact
ifn
treatment
suffici
reduc
prevent
replic
highli
pathogen
virus
upper
airway
virus
two
influenza
virus
high
pathogen
clade
avian
viru
reconstruct
pandem
viru
two
influenza
virus
low
pathogen
avian
viru
dkalb
human
isol
use
studi
avian
virus
propag
allanto
caviti
embryon
hen
egg
h
h
human
influenza
viru
strain
incub
addit
h
h
allanto
fluid
pool
multipl
egg
clarifi
centrifug
frozen
use
egg
infecti
dose
eid
determin
serial
titrat
viru
stock
egg
eid
ml
valu
calcul
accord
method
reed
muench
human
viru
stock
grown
mdck
cell
describ
previous
viral
titer
determin
standard
plaqu
assay
experi
use
viru
conduct
biosafeti
level
contain
http
includ
enhanc
requir
us
depart
agricultur
select
agent
program
anim
femal
hartley
strain
guinea
pig
weigh
g
obtain
charl
river
laboratori
frederick
md
challeng
studi
anim
hous
duoflo
bioclean
mobil
clean
room
lab
product
seaford
de
anim
allow
free
access
food
water
maintain
lightdark
cycl
prior
manipul
guinea
pig
anesthet
intramuscular
inject
mixtur
ketamin
mgkg
bodi
weight
xylazin
mgkg
anim
research
conduct
guidanc
center
diseas
control
prevent
institut
anim
care
use
committe
associ
assess
accredit
laboratori
anim
care
internationalaccredit
anim
facil
pathotyp
studi
assess
viru
pathogen
three
four
guinea
pig
inocul
intranas
eid
viru
instil
l
dilut
viru
nostril
implant
subcutan
temperatur
transpond
appli
previous
describ
guinea
pig
monitor
daili
chang
weight
temperatur
assess
virusinduc
morbid
nasal
wash
collect
day
pi
assess
replic
kinet
upper
airway
viru
nasal
wash
perform
instil
ml
phosphatebuff
salin
pb
contain
gml
penicillinstreptomycin
gibco
grand
island
ny
gml
gentamicin
gibco
bovin
serum
albumin
gibco
nostril
collect
liquid
runoff
steril
petri
dish
nasal
wash
immedi
frozen
dri
ice
store
titer
determin
determin
abil
viru
replic
lower
respiratori
tract
outsid
respiratori
tract
lung
spleen
tissu
harvest
three
addit
anim
day
pi
prior
collect
lung
spleen
sampl
anim
deepli
anesthet
describ
exsanguin
human
euthan
intracardiac
inject
beuthanasiad
solut
scheringplough
anim
health
corpor
kenilworth
nj
mlkg
tissu
sampl
titrat
remov
immedi
frozen
dri
ice
titer
analysi
tissu
sampl
homogen
ml
pb
contain
antibiot
gibco
tissu
homogen
clarifi
centrifug
viru
titer
determin
standard
plaqu
assay
serial
dilut
embryon
chicken
egg
describ
previous
time
harvest
remain
tissu
fix
formalin
evalu
histopatholog
guinea
pig
one
piec
spleen
one
four
piec
lung
tissu
immers
neutral
buffer
formalin
solut
routin
process
embed
paraffin
fivemicromet
section
stain
hematoxylin
eosin
duplic
section
immunohistochem
stain
demonstr
influenza
viru
nucleoprotein
use
mous
monoclon
antibodi
previous
describ
ifn
treatment
studi
ifn
use
studi
recombin
human
protein
previous
describ
shown
highli
activ
mice
recombin
protein
store
lyophil
reconstitut
immedi
prior
use
dose
ifn
correspond
ukg
averag
weight
anim
experi
previous
shown
effect
induc
antivir
state
among
treat
anim
given
intranas
volum
l
l
instil
nostril
ifn
dilut
pb
contain
antibiot
gibco
experi
involv
viru
challeng
challeng
dose
vari
pfu
eid
indic
singletreat
studi
ifn
provid
h
prior
viru
inocul
multipletreat
studi
guinea
pig
treat
ukgday
day
inocul
h
prior
inocul
h
initi
ifn
treatment
everi
day
day
pi
seroconvers
untreat
treat
guinea
pig
determin
test
sera
collect
day
pi
hemagglutin
inhibit
hi
assay
hors
dkalb
virus
turkey
virus
red
blood
cell
describ
previous
mx
protein
express
analysi
mx
protein
express
guinea
pig
lung
tissu
examin
follow
singl
ifn
treatment
ukg
viru
inocul
combin
ifn
treatment
follow
viru
challeng
last
group
anim
treat
ifn
pb
h
prior
inocul
eid
viru
describ
individu
guinea
pig
euthan
day
posttreatmentpostinfect
collect
lung
tissu
perform
describ
individu
lung
piec
collect
anim
area
repres
four
quadrant
upper
lower
right
left
side
western
blot
analysi
detect
mx
protein
express
level
extract
lung
tissu
carri
use
previous
describ
method
briefli
indic
time
point
lung
tissu
sampl
homogen
l
pb
contain
proteas
inhibitor
cocktail
sigma
st
loui
mo
follow
centrifug
pellet
resuspend
l
laemmli
buffer
biorad
hercul
ca
boil
min
protein
content
assay
spectrophotometr
nanodrop
spectrophotomet
thermo
scientif
wilmington
de
equal
amount
protein
load
sodium
dodecyl
sulfatepolyacrylamid
gel
immunoreact
protein
detect
use
antibodi
sigma
mxa
antibodi
incub
min
room
temperatur
overnight
respect
mxa
antibodi
use
mous
monoclon
antibodi
human
mxa
van
hoeven
et
al
j
virol
gener
hybridoma
cultur
supernat
kindli
provid
otto
haller
georg
koch
univers
freiburg
freiburg
germani
primari
antibodi
bind
detect
use
horseradish
peroxidaseconjug
antimous
immunoglobulin
g
heavypluslightchain
polyclon
antibodi
cell
signal
technolog
boston
accord
manufactur
protocol
investig
pathogen
highli
virul
avian
human
influenza
virus
guinea
pig
model
femal
hartley
strain
guinea
pig
inocul
four
virus
differ
pathogen
mice
ferret
virus
test
product
infect
guinea
pig
peak
viru
titer
nasal
wash
pfuml
eid
ml
day
pi
fig
tabl
dkalb
virus
persist
nasal
wash
day
pi
detect
level
day
pi
contrast
viral
titer
highli
virul
virus
persist
nasal
wash
day
pi
respect
fig
evalu
replic
virus
lower
respiratori
tract
guinea
pig
lung
tissu
collect
three
four
guinea
pig
per
viru
day
pi
influenza
viru
replic
peak
mammalian
model
four
influenza
virus
test
replic
guinea
pig
lung
without
prior
host
adapt
mean
lung
viral
titer
rang
eid
g
tabl
addit
evalu
viru
titer
physiolog
indic
viral
infect
monitor
durat
viru
shed
previou
studi
virus
shown
highli
pathogen
mice
ferret
caus
high
morbid
mortal
contrast
infect
guinea
pig
highli
virul
influenza
virus
caus
morbid
tabl
influenza
virus
highli
pathogen
model
guinea
pig
lung
patholog
mani
influenza
virus
high
pathogen
induc
sever
histopatholog
chang
pulmonari
extrapulmonari
tissu
mous
ferret
model
current
studi
lesion
lack
healthi
shaminocul
guinea
pig
fig
highand
lowpathogen
influenza
viru
strain
induc
lesion
lung
produc
minim
moder
bronchointerstiti
pneumonia
greatest
sever
adjac
hilu
dorsal
region
lung
lobe
peripheri
lung
lobe
least
sever
pneumonia
atelectat
normal
lung
parenchyma
fig
h
necrosi
bronchiolar
epithelium
associ
histiocytictoheterophil
inflamm
occasion
lumin
cast
present
termin
bronchiol
fig
lesion
less
common
bronchi
mani
bronchiol
bronchi
normal
alveolar
wall
thicken
infiltr
histiocyt
less
commonli
heterophil
edema
rare
fibrin
fig
alveolar
duct
occlud
cellular
debri
adjac
alveoli
fill
larg
foami
macrophag
fig
occasion
mix
inflammatori
cell
obscur
alveolar
wall
rare
hyalin
membran
present
fig
indic
sever
damag
alveolar
type
pneumocyt
influenza
viral
antigen
demonstr
infrequ
mainli
bronchiolar
epitheli
cell
histiocyt
within
area
pneumonia
fig
sever
pneumonia
guinea
pig
inocul
viru
fig
j
follow
viru
dkalb
viru
least
sever
lesion
occur
infect
taken
togeth
find
show
influenza
virus
high
low
pathogen
induc
pulmonari
lesion
guinea
pig
highli
pathogen
virus
induc
sever
lesion
addit
guinea
pig
compar
fewer
sever
lesion
report
ferret
mice
inocul
intranas
virus
guinea
pig
airway
epithelium
bronchi
upper
bronchiol
mildli
suscept
viru
infect
necrosi
compar
frequent
sever
necrosi
seen
termin
bronchiol
induct
mxa
protein
follow
treatment
guinea
pig
intranas
ifn
control
viru
replic
virul
influenza
viru
strain
lack
sever
lung
lesion
guinea
pig
suggest
anim
model
suit
studi
ifn
respons
influenza
viru
infect
possibl
function
mx
protein
guinea
pig
may
limit
influenza
viru
virul
model
could
use
develop
antivir
treatment
influenza
virus
pandem
potenti
determin
whether
exogen
ifn
capabl
induc
antivir
state
speci
examin
induct
mx
protein
follow
singl
treatment
recombin
human
western
blot
extract
lung
tissu
ifntreat
andor
guinea
pig
perform
monoclon
antibodi
direct
mxa
protein
fig
earli
h
follow
intranas
treatment
ukg
recombin
ifn
dose
ifn
previous
shown
induc
potent
antivir
state
mxposit
laboratori
mice
robust
induct
mx
protein
observ
ifntreat
anim
compar
pbstreat
anim
fig
top
panel
high
level
mx
protein
also
observ
h
posttreat
point
protein
level
slightli
declin
reduc
express
observ
h
posttreat
contrast
mx
profil
observ
guinea
pig
receiv
viru
infect
consist
found
intranas
infect
viru
result
induct
mx
protein
observ
h
pi
neglig
mx
protein
express
time
period
fig
bottom
panel
mx
protein
express
remain
high
day
viru
infect
anim
receiv
singl
dose
exogen
ifn
follow
viru
challeng
mx
protein
induc
h
pi
observ
h
pi
interestingli
comparison
experiment
group
receiv
ifn
viru
challeng
group
consist
display
reduct
mx
protein
express
day
pi
taken
togeth
result
show
ifn
treatment
viru
challeng
induc
potent
antivir
mx
protein
express
guinea
pig
lung
tissu
demonstr
exogen
ifn
treatment
could
induc
antivir
respons
guinea
pig
next
examin
abil
ifn
treatment
reduc
viral
titer
highli
pathogen
avian
human
influenza
viru
strain
speci
anim
treat
intranas
recombin
human
prior
follow
viru
inocul
day
pi
day
approxim
h
follow
ifn
treatment
four
anim
inocul
intranas
pfu
eid
viru
respect
reduc
dose
viru
chosen
base
previou
studi
use
season
influenza
viru
strain
guinea
pig
wherein
guinea
pig
infecti
dose
determin
expect
dose
viru
suffici
infect
untreat
control
anim
viru
recov
nasal
wash
untreat
anim
virusspecif
hi
antibodi
titer
present
sera
collect
anim
day
pi
tabl
strikingli
multiday
ifn
treatment
block
viru
infect
anim
inocul
low
dose
either
viru
fig
b
e
f
tabl
two
four
ifntreat
anim
group
possess
detect
antihi
serum
antibodi
larg
correl
detect
infecti
viru
recov
nasal
wash
anim
inocul
viru
anim
inocul
tabl
find
demonstr
ifn
treatment
abl
block
influenza
viru
infect
high
viru
input
dose
reduc
viru
replic
upper
airway
earli
viru
exposur
addit
evalu
viru
titer
examin
abil
ifn
treatment
prevent
virusinduc
pulmonari
lesion
follow
infect
less
sever
pneumonia
observ
anim
treat
ifn
prior
infect
moder
sever
bronchopneumonia
observ
untreat
anim
fig
patholog
observ
treat
anim
mild
fig
import
ifn
treatment
alon
result
sign
clinic
ill
gross
patholog
lung
tissu
section
examin
data
shown
reduct
viru
titer
follow
singl
treatment
guinea
pig
recombin
human
ifn
given
abil
multipl
dose
ifn
prevent
highli
pathogen
influenza
viru
infect
guinea
pig
next
evalu
abil
singl
dose
prophylact
administ
ifn
control
viru
infect
experi
recombin
human
ifn
pb
instil
intranas
administr
approxim
h
prior
inocul
fig
fig
eid
viru
follow
inocul
guinea
pig
eid
viru
ifntreat
anim
show
lower
nasal
wash
viral
titer
day
pi
titer
remain
lower
untreat
anim
day
pi
fig
subsequ
time
point
day
pi
viru
recov
elev
titer
nasal
wash
ifntreat
anim
titer
pbstreat
control
anim
declin
similar
pattern
viru
replic
observ
reduc
eid
challeng
dose
viru
fig
despit
viru
titer
recov
nasal
wash
gener
reduc
compar
anim
receiv
higher
viru
challeng
dose
ifntreat
anim
show
detect
viru
nasal
wash
day
pi
time
control
anim
show
averag
titer
pfuml
howev
viru
level
rebound
treat
anim
day
pi
viru
titer
declin
control
anim
time
fig
collect
studi
suggest
singl
dose
ifn
capabl
reduc
replic
clade
avian
isol
approxim
day
influenza
viru
pathogenesi
commonli
studi
laboratori
mous
domest
ferret
anim
model
influenza
viru
isol
frequent
group
two
class
base
sever
clinic
sign
induc
tissu
tropism
viru
virus
low
pathogen
mice
ferret
gener
caus
mild
ill
viru
replic
limit
respiratori
tract
morbid
character
weight
loss
virusinduc
clinic
sign
ruffl
fur
elev
temperatur
lethargi
follow
infect
infrequ
observ
virus
high
pathogen
typic
induc
high
morbid
weight
loss
mortal
frequent
associ
viru
spread
respiratori
tissu
brain
spleen
blood
note
highli
virul
influenza
virus
spread
system
viru
highli
lethal
inocul
ferret
mice
viru
replic
could
demonstr
extrarespiratori
tissu
unpublish
observ
guinea
pig
recent
emerg
altern
model
studi
transmiss
influenza
virus
ferret
remain
ideal
model
studi
mani
aspect
influenza
viru
infect
higher
cost
larg
amount
space
requir
hous
speci
sever
limit
number
anim
includ
individu
studi
given
rel
low
cost
reduc
size
guinea
pig
repres
suitabl
altern
host
studi
requir
larg
number
anim
multipl
treatment
group
thu
far
studi
guinea
pig
larg
perform
nonvirul
human
strain
current
studi
assess
virul
two
avian
influenza
viru
strain
well
two
human
influenza
virus
differ
pathogen
found
infect
guinea
pig
lowpathogen
virus
dkalb
result
minim
weight
loss
lethargi
chang
temperatur
cours
infect
tabl
surprisingli
virus
exhibit
high
level
virul
mice
ferret
macaqu
induc
signific
morbid
mortal
among
inocul
guinea
pig
despit
multiday
viru
shed
upper
airway
minim
weight
loss
observ
follow
viru
infect
viru
induc
morbid
time
cours
infect
dramat
reduct
virul
virus
observ
speci
allow
studi
identifi
host
genet
factor
respons
resist
lethal
influenza
viru
infect
possibl
function
mx
protein
guinea
pig
may
limit
viru
virul
highpathogen
phenotyp
gener
associ
virus
abro
gate
mice
possess
function
mx
gene
howev
virus
test
show
highpathogen
phenotyp
ferret
like
guinea
pig
possess
function
mx
gene
p
staeh
unpublish
observ
lack
widespread
sever
lung
lesion
induc
highli
pathogen
influenza
viru
isol
guinea
pig
may
help
explain
lack
morbid
mortal
observ
speci
mice
well
ferret
virus
found
induc
moder
sever
necrot
bronchiti
well
alveol
throughout
multipl
lung
lobe
moreov
distribut
histopatholog
lesion
mirror
distribut
viral
antigen
observ
bronchial
epithelium
throughout
lung
parenchyma
alveolar
cell
gener
influenza
viru
replic
lung
propos
lead
acut
lung
injuri
ultim
result
fatal
sever
acut
respiratori
distress
syndrom
howev
lung
lesion
guinea
pig
infect
viru
milder
report
infect
mice
ferret
mainli
restrict
parenchyma
surround
bronchiol
hilar
zone
dorsal
area
multipl
lung
lobe
antigen
rare
visual
bronchiolar
epithelium
found
success
infect
mammalian
respiratori
tract
influenza
virus
like
due
multipl
factor
includ
host
receptor
express
mani
studi
focus
identif
influenza
viru
target
cell
mammalian
airway
use
lectin
specif
bind
sialic
acid
moieti
serv
receptor
influenza
viru
collect
work
shown
receptor
avian
human
influenza
virus
asymmetr
distribut
throughout
respiratori
tract
gener
avian
human
influenza
viru
receptor
distribut
correl
abil
tissu
support
viru
replic
vivo
ex
vivo
bind
label
viru
particl
protein
tissu
section
although
note
replic
avian
virus
observ
excis
tissu
lack
obviou
receptor
thu
far
influenza
viru
receptor
distribut
guinea
pig
respiratori
tract
investig
although
studi
investig
sialic
acid
distribut
carri
context
fact
avian
sialic
acid
receptor
bind
prefer
human
sialic
acid
receptor
bind
prefer
virus
could
isol
similar
high
titer
nasal
wash
suggest
type
sialic
acid
receptor
present
guinea
pig
respiratori
tract
ferret
human
tissu
receptor
bound
human
influenza
virus
restrict
primarili
upper
respiratori
tract
wherea
receptor
preferenti
bound
avian
virus
abundantli
present
lung
parenchyma
respiratori
epithelium
ifn
treatment
current
employ
treatment
chronic
hepat
c
viru
infect
also
shown
promis
potenti
therapeut
virus
hepat
b
viru
sever
acut
respiratori
syndrom
coronaviru
recent
beilharz
et
al
show
low
oral
dose
deliv
daili
prophylact
therapi
protect
mice
lethal
challeng
mouseadapt
viru
anoth
studi
singl
prophylact
ifn
treatment
given
intranas
effect
reduc
viru
titer
follow
challeng
effect
depend
mx
protein
singl
ifn
treatment
significantli
reduc
titer
viru
mx
mx
mous
lung
guinea
fig
ifn
treatment
regimen
expand
includ
multipl
ifn
dose
infect
fulli
block
challeng
anim
determin
lack
viral
isol
absenc
seroconvers
inocul
viru
studi
present
assess
use
ifn
prophylact
treatment
reduc
viral
load
postinfect
suggest
would
possibl
block
influenza
viru
infect
exogen
ifn
also
import
futur
studi
determin
efficaci
therapeut
ifn
treatment
initi
follow
infect
prevent
morbid
subsequ
transmiss
influenza
virus
howev
consid
applic
studi
human
treatment
pandem
import
ifn
treatment
human
associ
number
advers
side
effect
make
multipl
treatment
high
dose
ifn
potenti
unten
appear
frequent
advers
event
could
correct
reduc
total
dose
ifn
provid
cours
treatment
studi
present
suggest
guinea
pig
use
model
test
effect
lower
dose
ifn
attempt
develop
multipledos
treatment
regimen
could
adapt
use
human
furthermor
exclus
use
highdos
ifn
antivir
treatment
highli
pathogen
influenza
viru
infect
human
may
impract
result
demonstr
singl
high
dose
ifn
may
use
suppress
viru
titer
replic
earli
time
point
postinfect
could
allow
bioaccumul
specif
influenza
viru
antivir
oseltamivir
transient
reduct
titer
may
use
prevent
transmiss
uninfect
person
help
slow
spread
viru
pandem
final
becom
import
investig
use
ifn
treatment
therapeut
prophylact
combin
influenza
virusspecif
antivir
mean
limit
viru
replic
combin
therapi
use
model
promis
result
may
circumv
potenti
harm
effect
multidos
highlevel
ifn
treatment
one
import
mechan
ifn
respons
pathway
establish
antivir
state
establish
posit
feedback
loop
infect
cell
bind
ifn
cell
result
increas
product
secret
ifn
turn
act
produc
cell
neighbor
cell
review
refer
interest
studi
virus
seem
abl
overcom
feedback
loop
high
low
viru
challeng
dose
viru
replic
reduc
delay
singledos
ifn
treatment
eventu
rebound
reach
level
similar
observ
pbstreat
control
fig
b
multipl
ifn
treatment
studi
ifn
unabl
prevent
infect
reduc
titer
similar
find
observ
antivir
studi
demonstr
high
challeng
dose
may
overwhelm
exogen
host
antivir
respons
achiev
effici
replic
despit
inhibit
antivir
compound
host
respons
protein
virus
shown
especi
potent
suppressor
ifn
respons
reassort
virus
contain
gene
virus
show
increas
pathogen
mice
compar
parent
strain
abil
overcom
singledos
ifn
treatment
demonstr
support
previou
work
murin
system
demonstr
ns
protein
virus
highli
effect
counter
ifn
system
dissect
ifn
respons
guinea
pig
detail
analysi
antagon
system
use
reassort
virus
would
necessari
implic
dissect
virul
factor
guinea
pig
conclus
find
present
seek
determin
whether
guinea
pig
provid
use
small
anim
model
studi
influenza
viru
pathogenesi
whether
model
could
use
develop
antivir
treatment
could
test
virus
pandem
potenti
establish
influenza
virus
low
high
virul
capabl
infect
guinea
pig
isol
induc
spectrum
patholog
chang
lung
tissu
similar
observ
anim
model
howev
absenc
sever
diseas
observ
follow
infect
highli
pathogen
virus
suggest
guinea
pig
may
limit
util
studi
influenza
viru
pathogenesi
nonetheless
abil
guinea
pig
respond
exogen
ifn
treatment
suggest
model
would
use
develop
novel
therapeut
strategi
especi
would
difficult
expens
test
larger
anim
model
import
role
antivir
drug
influenza
pandem
slow
viru
replic
subsequ
spread
appropri
vaccin
product
